Sharon Patibandla
Medical · Clifton, NJNPI 1760044796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 28.6% of the total. 2025 is the largest year on record at $2,464, 2.1 times the $1,201 reported in 2021. Among medical clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $29.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- GSK$1K
- Novo Nordisk$742
- Amgen$734
- Ironwood Pharmaceuticals, Inc$560
- plus $2K from 21 others
What the payments were for
- Food & beverage$9,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $2,818 |
| Boehringer Ingelheim | 38 | $1,681 |
| GSK | 74 | $1,478 |
| Novo Nordisk | 42 | $742 |
| Amgen | 25 | $734 |
| Ironwood Pharmaceuticals, Inc | 8 | $560 |
| Lilly USA, LLC | 18 | $274 |
| AbbVie | 10 | $265 |
| Bayer | 11 | $252 |
| Merck | 14 | $218 |
| Teva Pharmaceuticals USA, Inc. | 2 | $160 |
| Sanofi-aventis U.S. LLC | 8 | $107 |
| Johnson & Johnson | 1 | $101 |
| Novartis | 6 | $91 |
| Dexcom, Inc. | 4 | $83 |
| Azurity Pharmaceuticals, Inc. | 3 | $50 |
| Genentech USA, Inc. | 4 | $43 |
| Amarin Pharma, Inc. | 3 | $40 |
| Pfizer | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Exact Sciences | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,865 in reported general payments places this provider in the 95th percentile of 573 medical providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 107 | $92,056 |
| JardianceEmpagliflozin | 67 | $61,574 |
| OzempicSemaglutide | 43 | $45,348 |
| JanuviaSitagliptin Phosphate | 46 | $31,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $25,008 |
| MyrbetriqMirabegron | 32 | $20,861 |
| DapagliflozinDapagliflozin Propanediol | 38 | $20,685 |
| TrulicityDulaglutide | 21 | $19,110 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $14,986 |
| KerendiaFinerenone | 14 | $13,549 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $13,164 |
| EliquisApixaban | 15 | $12,081 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $11,703 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,059 |
| EntrestoSacubitril/Valsartan | 11 | $9,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $2,818 | $102,116124 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $1,681 | $69,87478 claims |
| Novo NordiskOzempic | $742 | $45,34843 claims |
| MerckJanuvia, Janumet | $218 | $43,00862 claims |
| GSKTrelegy Ellipta, Shingrix | $1,478 | $29,66464 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $20,86132 claims |
| Lilly USA, LLCTrulicity | $274 | $19,11021 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $107 | $14,98619 claims |
| BayerKerendia | $252 | $13,54914 claims |
| PfizerEliquis | $29 | $12,08115 claims |
| NovartisEntresto | $91 | $9,92111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 medical providers in New Jersey.
Other medical in Clifton
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
- Shane CourtneyLinwood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.